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T he prostatitis patient represents one of the biggest clinical conundrums in urology today. Patient anxieties, beliefs and fears are fuelled by a lack of knowledge and understanding of the condition by healthcare professionals.
Almost 20 years ago, Dr J. Curtis Nickel commented in an article published in Urology that many urologists would be happy to never see another prostatitis patient again. 1 His view of the care delivered was that it tended to ignore the real issue, and generally involved dispensing the 'antibiotic of the month' and discharging the patient quickly. Some would argue that, since the article first appeared back in 1998, not much has changed.
Prostatitis accounts for 25% of visits to urologists. It is the most common urological diagnosis in males under 50, and the third most common in males over 50. 2 The National Institutes of Health in the United States classifies prostatitis into four distinct categories (Table 1) , 3 with type III chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) accounting for over 90% of cases. CP/CPPS patients are not homogenous; each individual presents with their own complex case, often developing into a confusing and vicious cycle of symptom escalation and increased desperation. With most men suffering from prostatitis at least once in their lifetime, the need for clarity in diagnosis and successful outcomes is paramount.
INITIAL ASSESSMENT
NICE guidelines offer little differentiation between treatment and management protocols for bacterial and non-bacterial prostatitis as advised by the Prostatitis Expert Reference Group (PERG). 4 Both NICE and PERG advise a referral to a urologist, stool softener, non-steroidal antiinflammatory drugs (NSAIDs) and a single four-to six-week course of antibiotics. For the CP/CPPS patient, a single four-to six-week course of alpha-blockers is also advised, although not in combination with antibiotics. PERG guidelines for the treatment of CP/CPPS strongly advise against the unnecessary repeat prescription of NSAIDs, alpha-blockers and antibiotics if ineffective in reducing patient symptoms, in order to prevent unwanted side-effects. 4 Overall, alpha-blockers have shown mixed results as a standalone treatment in the clinically significant reduction of CP/CPPS symptoms, with even greater limitations in long-standing CP/CPPS patients. 5 Empirical antibiotic therapy for prostatitis is widely used, yet the evidence for its success in treating CP/CPPS is very weak. Metaanalysis failed to show any statistically The four-glass Meares-Stamey test was always considered the gold standard, yet 80% of urologists reported that they 'rarely' or 'never' performed the test. 7 Those who routinely used the four-glass test did not differ in antibiotic use from those using it less. The four-glass test has historically proven to be fiddly and complex. The alternative two-glass or pre-and postprostate massage test (PPMT) (Figure 1 ) has shown a 96% accuracy rate in identifying the presence of bacterium when compared with the four-glass test. 8 Differentiating true prostatitis from non-bacterial syndromes requires the development of accurate diagnostic tests. 9 In order to gather clear and relevant data, these tests must be carried out before any antibiotic therapy has commenced. Used in isolation, the PPMT has its limitations; however, when used in combination with other diagnostic tools, it can be a valuable asset.
THE 'I' IN PAIN
The term 'prostatitis' has been used as an umbrella term to describe a collection of pain symptoms in and around the pelvis. In many cases, the prostate is simply not involved. It is archaic, and does not truly represent the pain presentations of CP/CPPS patients. Unless a true infection or inflammation has been identified, the term 'prostatitis' is spurious. Identifying pain in the pelvis and associated organs as being driven by the prostate is particularly misleading. This confusion over the relationship of the prostate and a patient's symptoms can lead to maladaptive behaviour. A clear, appropriate and accurate diagnosis provides the patient with clarity, and a feeling of being understood and listened to, as well as hope for future recovery.
Beneath the clinical presentation, diagnosis and prescriptions, it is important to remember that there is an individual. The current biomedical model used to treat CP/CPPS is incomplete. Flaws and discrepancies, along with inconsistencies in education around the condition, result in patients becoming confused and agitated. The biopsychosocial model looks beyond the Cartesian separatist view of the body and mind, and considers the patient's unique psychological and biological make-up, coping strategies, fears, anxieties and behaviours. It also takes into account the impact of their condition on their social and employment status, and financial implications. Fear avoidance, beliefs and distressing thought patterns around CPPS negatively influence a patient's progress and recovery.
The role of the healthcare professional in the management of the CP/CPPS patient's concerns, anxieties and negative thought patterns is central. A perceived negative approach can result in frustration and anger. 1 The psychological impact of prostatitis is well documented. CP/CPPS symptom distress and reduction in quality of life is comparable with congestive heart failure, Crohn's disease, diabetes mellitus and angina. 10 Suicidal thoughts are not uncommon in this population of men.
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The distress, anguish and fear of not understanding their problem or having a clear treatment path is simply too much for some.
Catastrophisation has a robust relationship with CP/CPPS pain and pain adjustment. Considered together, pain, relationships and quality of life suggest that a biopsychosocial model of intervention is warranted. A model that only focuses on one of these variables is arguably incomplete. 12 It is important, however, when using the biopsychosocial model in treating CP/CPPS, not to neglect any pathophysiological presentations.
CLARITY THROUGH CLASSIFICATION
The grading of prostatitis using the symptom-focused NIH-CPSI has proven far too vague to date. The 'UPOINT' system classification (urinary, psychosocial, organspecific, infection, neurologic/systemic, tenderness of skeletal muscles) offers a holistic approach to the treatment of the CP/CPPS patient. 13 Dividing patients into clinically relevant phenotypes, its aim is to increase the successful management of bladder and prostate syndromes through greater understanding and reflection. UPOINT enables the practitioner to diagnose and classify CP/CPPS syndromes and develop a tailored, multimodal treatment plan.
The six domains in the UPOINT system (Box 1) are each assigned a specific treatment targeted to the specific symptoms characteristic of that domain. Initial studies suggest that the multimodal treatment guided by UPOINT leads to a significant improvement of symptoms and quality of life. 13 It has been suggested that adding a domain for sexual dysfunction (assessment of erectile and orgasmic dysfunction, impaired sexual desire and intercourse satisfaction/UPOINTS) could further enhance the classification system. 14 
CONCLUSION
In the November/December 2015 edition of Trends in Urology & Men's Health, Professor Roger Kirby highlighted the necessity of developing better diagnostic tools beyond the PSA test and unnecessary prostate biopsies for prostate cancer patients. 15 The same principles must be applied in the diagnosis and treatment of prostatitis. Greater identification of patient subgroups through UPOINT(S) can provide a range of phenotypically targeted treatment options, resulting in a significant reduction of symptoms and an increase in quality of life. Greater public awareness, charity action and targeted research will additionally nurture this process to future success. Although there is still much ground to cover in terms of a clear treatment paradigm, there is finally a suggestion of light at the end of the tunnel.
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